DENOSUMAB- A REVIEW OF ITS USE IN THE TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS
Journal: Indo American Journal of Pharmaceutical Sciences (IAJPS) (Vol.2, No. 3)Publication Date: 2015-03-30
Authors : Srijita Dutta;
Page : 621-627
Keywords : Denosumab; Post menopause; Osteoporosis; Fractures;
Abstract
Abstract: Denosumab is a human recombinant monoclonal antibody that is approved for the treatment of postmenopausal osteoporosis in women at high or increased risk of fracture in the US, the EU and several other countries. Denosumab binds to receptor activator of nuclear factor κB ligand and inhibits bone resorption by inhibiting osteoclast formation, function and survival. In postmenopausal women with low bone mineral density (BMD) or osteoporosis, treatment with denosumab increased BMD and decreased markers of bone turnover more than alendronate in those who were switched from alendronate to denosumab or continued alendronate treatment. In this review article the guidelines for pharmacologic properties, clinical efficacy, and safety profile of the injectable agent denosumab for the treatment of postmenopausal women with osteoporosis are discussed. Keywords: Denosumab, Post menopause, Osteoporosis, Fractures
Other Latest Articles
Last modified: 2015-03-30 21:30:44